Ozempic and Kidney Disease: FDA Use, FLOW Results, Risks

Is Ozempic bad for your kidneys, or good for them? For most people it is good, or at least neutral, and for one group it is FDA-approved kidney protection. Since January 28, 2025, Ozempic (semaglutide) has been approved to lower the risk of losing kidney function, reaching kidney failure, and dying from heart disease in adults with type 2 diabetes and chronic kidney disease (CKD). The real kidney risk on the label is short-term: acute kidney injury when vomiting or diarrhea dries you out. Here is what the FDA label and the FLOW trial actually say.

What is the Ozempic kidney indication?

The Ozempic label, last revised in July 2026, lists three uses. The third one is kidney related. Ozempic is approved "to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease."

In plain words:

• eGFR is the number from your blood test that shows how well your kidneys filter. Lower means weaker kidneys.
• End-stage kidney disease means the kidneys have failed and you need dialysis or a transplant.
• Who it covers: adults with both type 2 diabetes and CKD. It does not cover kidney disease without diabetes, and it is not a treatment for kidney disease in people taking it only for weight loss.

Novo Nordisk said at the time that this made Ozempic the only GLP-1 drug with a kidney outcome indication. If you want the bigger picture of how it works on blood sugar, see our guide to GLP-1 medications and type 2 diabetes.

What did the Ozempic kidney trial (FLOW) find?

FLOW was a large trial built to answer one question: does semaglutide slow kidney disease? It enrolled 3,533 adults with type 2 diabetes and CKD. Their average eGFR was 47, and 11% had an eGFR under 30, which is advanced disease. Almost everyone (95%) was already on a standard kidney-protecting blood pressure pill (an ACE inhibitor or ARB). Half got Ozempic 1 mg once a week and half got placebo, and they were followed for a median of 41 months. The trial stopped early because the benefit was clear.

Here are the results from the label's FLOW table:

Two honest notes. First, the drop in dialysis by itself was small and not statistically clear; the benefit was strongest for slowing eGFR loss and for heart deaths. Second, only 16% of people were on an SGLT2 inhibitor (like Jardiance or Farxiga), another kidney-protecting drug. The label says the benefit "was not evident" in that small group, but there were few events, so we cannot say much either way.

The heart results line up with what other semaglutide trials found. Our GLP-1 and cardiovascular health guide covers SELECT.

Can Ozempic cause kidney damage or kidney failure?

This is the worry behind searches like "ozempic kidney damage" and "ozempic kidney failure." The label does carry a warning, and it is specific:

• What: acute kidney injury (a sudden drop in kidney function), in some cases needing dialysis. These were reports after the drug was on the market.
• Why: volume depletion. Nausea, vomiting and diarrhea, the most common GLP-1 side effects, can drain fluid fast. Kidneys need steady blood flow, and dehydration cuts it.
• When: mostly while starting Ozempic or moving up a dose.
• What doctors are told to do: check kidney function in anyone with side effects that could dry them out.

So the risk is real but tied to fluid loss, not to the drug slowly harming the kidneys. The label also says no dose change is needed for any level of kidney function, including kidney failure, because semaglutide levels do not change much in people with weak kidneys.

Call your doctor if you cannot keep fluids down for a day, pee much less than usual, feel dizzy when you stand, or notice swelling. Our guides on managing nausea on Ozempic and hydration on GLP-1 have practical steps.

Does Ozempic cause kidney stones?

Kidney stones are not listed as a side effect in the Ozempic label. There is no strong trial signal that semaglutide causes them. But two things can raise the odds for anyone on a GLP-1:

• Drinking less. The drug quiets thirst along with hunger, and low fluid intake is one of the main causes of stones, per the NIH (NIDDK).
• Fast weight loss and big diet changes, such as very high meat intake with few fruits and vegetables.

A simple goal is pale yellow urine through the day. If you have sharp pain in your side or back, blood in your urine, or fever and chills, get checked.

Ozempic kidney dose and how it is taken

Per the label, for adults with type 2 diabetes and CKD:

This is the label schedule, not personal advice. Your prescriber may move slower if side effects are hard. For every Ozempic and Wegovy dose in one place, see our semaglutide dosage chart.

Is Ozempic safe if you already have kidney disease?

FLOW included people with eGFR as low as 25, and the drug helped them. That is a strong safety signal for people with diabetes and CKD. Still, a few groups need extra care with their kidney doctor:

• People with an eGFR under 25 or on dialysis, who were not in FLOW.
• People also taking diuretics (water pills), which add to fluid loss.
• People who already get dehydrated easily.

The trial left out some kidney diseases, such as polycystic kidney disease and glomerulonephritis, so results may not apply there.

Protein and kidney disease on a GLP-1

Most GLP-1 advice says to eat more protein to protect muscle. If you have CKD, that advice needs a kidney check first. The KDIGO 2024 kidney guideline suggests about 0.8 grams of protein per kilogram of body weight a day for adults with CKD stages 3 to 5 who are not on dialysis, and avoiding more than 1.3 g/kg a day for people whose kidney disease may get worse. That is less than the 1.2 to 1.6 g/kg range often suggested for people on GLP-1s with healthy kidneys. Our protein target guide explains the general numbers.

The good news: muscle is protected by strength training as well as protein. If your kidney team sets a lower protein number, short resistance workouts matter even more. Sharpy lets you hold one protein target, whatever number your care team gives you, and pairs it with one 20-minute workout a day so your muscle gets the signal to stay.

Wegovy, Mounjaro and Zepbound: do they help kidneys too?

Wegovy has the same active drug, but the kidney indication is only on the Ozempic label because FLOW tested Ozempic in people with diabetes. Our GLP-1 medication comparison lays out the other differences.

The bottom line

Ozempic is FDA-approved to protect the kidneys of adults with type 2 diabetes and chronic kidney disease, and in FLOW it lowered the risk of serious kidney and heart events by 24%. The main kidney danger is dehydration during bad stomach side effects, so drink steadily and tell your doctor if you cannot keep fluids down. If you have CKD, get your protein number from your kidney team before following general GLP-1 advice. Then use Sharpy to hit that number and do your 20-minute workout, so the weight you lose comes from fat, not muscle.

Sources

• Ozempic (semaglutide) injection prescribing information, revised July 2026 (openFDA)
• Novo Nordisk: FDA approves Ozempic to reduce the risk of worsening kidney disease, January 28, 2025 (BioSpace)
• Patient Care: FDA approves new indication for semaglutide to lower kidney risks, January 28, 2025
• NephJC: The KDIGO 2024 CKD Guidelines, part 2 (protein intake)
• NIDDK: Symptoms and causes of kidney stones